# References of the poster 
## entitled "Building predictive models for immunotherapy response in urothelial carcinoma"

### by Lilian Marie Boll
### ACGT retreat April 13th and 14th 2023

1. Litchfield et al., (2021). “Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.”. Cell .
https://www.sciencedirect.com/science/article/pii/S0092867421000027

2. Powles et al. (2021). "Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 tria.l". Nat Med.
https://www.nejm.org/doi/full/10.1056/NEJMoa2002788

3. Lopez-Beltran et al. (2021). “Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.”. Cancers .
https://pubmed.ncbi.nlm.nih.gov/33401585/

4. Mariathasan et al., (2018). "TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.". Nature.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028240/

5. Miao et al., (2018). "Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors". Nat Genet.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119118/

6. Cristescu et al., (2018). "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy". Science.
https://pubmed.ncbi.nlm.nih.gov/30309915/

8. Ayers et al., (2017). "IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade". J Clin Invest.
https://pubmed.ncbi.nlm.nih.gov/28650338/

9. Snyders et al., (2017). "Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis". PLoS Med.
https://pubmed.ncbi.nlm.nih.gov/28552987/
